

20 Running Title: Clinical performance of COVID-19 Molecular Tests

21

22

23 #Address correspondence to:

24 Jorge Sepulveda, MD, PhD

25 PH1564

26 622 W 168 St

27 New York, NY 10032

28 212-305-6360

29 jls2282@cumc.columbia.edu

30

31 **Abstract**

32 Molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
33 gold standard for diagnosis of coronavirus disease 2019 (COVID-19), but the test clinical
34 performance is poorly understood. From 3/10/2020-5/1/2020 NewYork-Presbyterian
35 laboratories performed 27,377 SARS-CoV-2 molecular assays from 22,338 patients. Repeat
36 testing was performed in 3,432 patients, of which 2,413 had negative and 1,019 had
37 positive first day results. Repeat-tested patients were more likely to be older, male, African-
38 American or Hispanic, and to have severe disease. Among the patients with initially
39 negative results, 18.6% became positive upon repeat-testing. Only 58.1% of any-time
40 positive patients had a result of “detected” on the first test. The clinical sensitivity of
41 COVID-19 molecular assays is estimated between 66.2 % and 95.6%, depending on the
42 unknown number of false negative results in single-tested patients. Conversion to a
43 negative result is unlikely to occur before 15 to 20 days after initial testing or 20-30 days
44 after the onset of symptoms, with 50% conversion occurring at 28 days after initial testing.
45 Forty-nine initially-positive patients converted to negative and then back to positive in
46 subsequent days. Conversion from first day negative to positive results increased linearly
47 with each day of testing, reaching 25% probability in 20 days. In summary, our study
48 provides estimates of the clinical performance of SARS-CoV-2 molecular assays and
49 suggests time frames for appropriate repeat testing, namely 15 to 20 days after a positive
50 test and the same or next 2 days after a negative test in a patient with high suspicion for
51 COVID-19.

52

53

54 **Introduction**

55 Coronavirus disease 2019 (COVID-19) which is caused by severe acute respiratory
56 syndrome coronavirus 2 (SARS-CoV-2) (1, 2) is a global pandemic with mortality
57 significantly higher than seasonal influenza (3). The rapid sequencing of SARS-CoV-2
58 genomes (1, 2) has allowed the development of multiple real-time reverse transcription-
59 polymerase chain reaction (RT-PCR) assays that have become the gold standard to detect
60 viral RNA and identify patients with COVID-19 as well as asymptomatic carriers. However,
61 some patients with positive chest radiologic findings and symptoms suspicious for COVID-
62 19 have been reported to test negatively by SARS-CoV-2 RT-PCR and require multiple
63 consecutive tests to convert to a positive result (4, 5). There is limited information on the
64 clinical performance characteristics of the SARS-CoV-2 molecular tests in real world cases,
65 namely what is the predictive value of a negative result in patients suspected of COVID-19
66 and what is the relationship between the course of the disease, viral shedding, and
67 positivity of the various molecular assays. During the 2020 pandemic of COVID-19, we
68 tested 27,377 samples from 22,338 patients with SARS-CoV-2 molecular assays performed
69 at NewYork-Presbyterian (NYP) clinical laboratories. The assays used in this patient
70 population included six platforms based on reverse-transcription and nucleic acid
71 amplification to detect SARS-CoV-2 specific RNA sequences. Our goal is to identify the
72 clinical performance characteristics of SARS-CoV-2 molecular assays for diagnosis and
73 stratification of COVID-19 patients and determine the dynamics of SARS-CoV-2 molecular
74 assay results over time in a large dataset from multiple hospital locations in the New York
75 City area.

76 **Methods**

77 **Laboratory Dataset**

78 We extracted records of all the SARS-CoV-2 tests performed at NYP laboratories from our
79 laboratory information system (Cerner Millennium, Cerner Corporation, North Kansas City,
80 MO) using a custom Cerner Command Language query. We tested a total number of 22,338
81 patients between March 10, 2020 and May 1, 2020 for SARS-CoV-2 by molecular assays at
82 NewYork-Presbyterian affiliated hospitals and performed a total of 27,377 assays on
83 nasopharyngeal (initially also on oropharyngeal) swab samples. The vast majority of the
84 SARS-CoV-2 tests were reverse-transcription real time PCR assays performed with the
85 high-throughput automated cobas 6800 (Roche Molecular Systems, Branchburg, NJ)
86 platform (N=19,195), which went live at Columbia-NYP laboratory on 3/15/2020 and at
87 Cornell-NYP laboratory on 3/30/2020. A smaller number of assays were performed since
88 3/10/2020 with in-house developed tests under FDA Emergency Use Authorization using
89 the Rotor-Gene Q (N=1795, Qiagen, Valencia, CA) and 7500 Fast (N=89, Thermo-Fisher
90 Scientific, Waltham, MA) instruments. From 4/3/2020 thereafter other platforms were
91 introduced in the NYP laboratories, including the Xpert Xpress SARS-CoV-2 test analyzed
92 on the GeneXpert (N=265) and Infinity (N=5954) platforms (Cepheid, Sunnyvale, CA), the
93 ID Now (N=53), (Abbott, Chicago, IL) and the Panther Fusion (N=26) (Hologic Inc., San
94 Diego, CA) instruments. Commercial molecular viral assays were validated and performed
95 at NYP Hospital Laboratories following manufacturers' recommendations.

96 **Patients**

97 The NYP laboratory SARS-CoV-2 testing dataset contains basic demographic information
98 on each patient, including age, gender, race, and health care encounter type and location at
99 the time of order. To better understand SARS-CoV2-2 test utilization and investigate the

100 association with clinical information to the SARS-CoV-2 test results on a subset of patients,
101 we merged our laboratory dataset with the Columbia COVID-19 CARE clinical database.
102 The COVID-CARE clinical database is an interdisciplinary database, managed by the
103 Columbia Division of Infectious Diseases and contains data on all patients tested for SARS-
104 CoV-2 at the New York Presbyterian West Campus (Milstein Hospital, Allen Hospital,
105 Morgan Stanley Children’s Hospital). This interdisciplinary database contains the work of
106 numerous divisions within the Departments of Medicine, Pediatrics, Neurology, and
107 Obstetrics and Gynecology. The database is comprised of a general primary instrument
108 and multiple sub-specialty instruments resulting in over 720 curated fields per patient.
109 Data was extracted from the medical record through manual review by a team of medical
110 students and sub-specialty fellows and attendings. Manually curated data is combined with
111 structured data from the electronic medical records, pharmacy, and laboratory systems to
112 complete the dataset. As of May 1st 2020, 1,624 patients had undergone manual review
113 (Supplementary Table 1).

114 Clinical factors and other patient characteristic are compared between SARS-CoV-2
115 positive and SARS-CoV-2 negative patients in Supplementary Table 2, and between repeat-
116 tested and single-tested patients in Supplementary Table 3. This study was approved by
117 the Institutional Review Boards of Columbia and Cornell Universities.

118

119 **Data Analysis**

120 Categorical data was presented as frequency and percent. Continuous data was presented
121 as mean (standard deviation) or median and range. Differences between groups were
122 compared using Chi-square tests for categorical variables, and linear ANOVA for
123 continuous variables. Correction for multiple testing was performed using the false

124 discovery rate method of Benjamini-Hochberg (6). Confidence intervals for sensitivity and
125 negative predictive values were calculated using the *epiR* R package. Time to event using
126 Kaplan Meier curves were used to investigate time to conversion from initially negative to
127 positive and from initially positive to negative. All statistical analyses were performed
128 using the R statistical language (7).

129 **Results**

130 A total of 18,906 assays were performed once per patient and 8,471 assays were
131 performed in 3,432 (15.4%) patients with more than one test completed in the span of 1 to
132 49 (median = 8) days between assays. There were 2,280 patients with multiple SARS-CoV-2
133 molecular assays performed who had a first negative, invalid, or indeterminate result and
134 797 patients who had an initial positive result.

135 **Demographic and clinical characteristics**

136 Patients with any positive SARS-CoV-2 result differed from those that were never positive
137 for SARS-CoV-2 even with repeat testing (Supplementary Table 2). Notably, SARS-CoV-2
138 positive patients were more likely to be male, older than 44 years, and of self-reported
139 African-American or Hispanic / Latino ethnicity and less likely to be Asian or Caucasian
140 (Supplementary Table 2, all $p < 0.001$). Not surprisingly, severe disease was more likely in
141 SARS-CoV-2 positive patients, as indicated by a higher fatality rate (6.2% vs. 3.8%,
142 $p = 0.048$), presence of symptoms (91.8% vs. 72.4%, $p = 0.004$), need for intubation (10.7%
143 vs. 7%, $p = 0.026$) and frequency of decompensation, as defined by an outcome of
144 intubation, death, or discharge to hospice (13.4% vs. 8.4%, $p = 0.005$).

145 To determine which factors were associated with repeat testing for SARS-CoV-2 we
146 analyzed demographic and clinical features of repeat-tested as compared to single-tested

147 patients (Supplementary Table 3). Our data show higher age (median = 59.9 vs. 53.4,
148 $p < 0.001$), higher frequency of male gender (52.2% vs. 44.3%, $p < 0.001$), and different
149 distribution of self-reported race and ethnicity in repeat-tested as compared to single-
150 tested patients, with African-Americans and Hispanics / Latinos being more likely to be
151 repeat-tested ($p < 0.001$). At the time of the first test order, admitted patients were
152 significantly more represented in the repeat-tested population in contrast to patients
153 visiting the emergency department and outpatients ($p < 0.001$). Compared with single-
154 tested patients, repeat-tested patients were 3.2 times more likely to be admitted to the ICU
155 (29.7% vs. 9.4%, $p < 0.001$), 4 times more likely to be intubated (24.4% vs. 6.1%, $p < 0.001$),
156 3.4 times more likely to decompensate (27.6% vs. 8.1%, $p < 0.001$) and 1.7 times more likely
157 to die during the observation period (8% vs. 4.7%, $p = 0.038$).

158 **SARS-CoV-2 Test Performance**

159 The characteristics of the SARS-CoV-2 tests performed in repeat-tested compared to single-
160 tested patients are described in Supplementary Table 4. The vast majority of tests were
161 performed with the cobas 6800 and the use of the various assays was not significantly
162 different between repeat and single-tested patients, except for a small number of patients
163 initially tested with the Thermo-Fisher 7500 assay, which was more likely in repeat-tested
164 patients ($p < 0.001$, standardized Pearson residuals for repeat-tested patients = 3.9).

165 Among all the repeat-tested patients, 23.2% were positive on the first test (26.5% when
166 indeterminate results were included). If a negative test was repeated on the first day, the
167 positivity rate increased to 26.4% (29.7% with indeterminate results). Overall positivity
168 among repeat-tested patients over the course of the study period was 39.9% in contrast to
169 49% for single-tested patients ($p < 0.001$). When indeterminate results were counted as

170 positive, 42.9% of repeat-tested patients were positive over the course of the study period
171 in contrast to 50% of single-tested patients ($p<0.001$).

172 Indeterminate results are generally considered presumptive positive and occur when only
173 one of two molecular targets is detected. In our repeat-tested patients with an initial result
174 of “Indeterminate”, 54.4% ultimately had a result of “Detected”, as compared to 7% that
175 remained indeterminate upon repeat testing and 38.6% that converted to a negative status
176 during our study period, thus suggesting that it is acceptable to consider these patients
177 positive. However, it is unclear whether the initially indeterminate patients that converted
178 to negative were false positives or presented with low viral loads.

179 In contrast, a result of “Invalid” reflects the failure to amplify the built-in control and is
180 likely related to poor sampling or inadequate RNA extraction usually due to high viscosity
181 of the samples. In our study of repeat test patients, 52.7% ultimately became positive, 1.2%
182 repeated as “Indeterminate” and 45.6% repeated as ‘Not Detected’. For the analysis of
183 clinical sensitivity of SARS-CoV-2 molecular tests, we considered patients with invalid
184 results as “negative”, as these results can be considered clinically false negatives in the
185 sense that the patient may be infected and the test failed to yield a positive result. In
186 practice, invalid results should always be repeated, preferably with a new sample, as the
187 results are unpredictable.

188 Initial negative, invalid, or indeterminate SARS-CoV-2 test results were much more
189 frequent among repeat-tested patients (Supplementary Table 4, $p<0.001$) and conversely,
190 patients without a positive initial result were more likely to be repeated (21%) than
191 initially positive patients (8%, $p<0.001$).

192 A subset of the cobas 6800 tests ($N=5,343$) had cycle threshold (Ct) values available for
193 analysis. The Ct represents the PCR cycle, interpolated to two decimal digits, at which the

194 real-time fluorescent signal crosses a pre-defined threshold for positivity. The Ct is
195 inversely proportional to the concentration of viral RNA. The cobas SARS-CoV-2 RT-PCR
196 assay amplifies two specific targets: Target 1 is located in the ORF1ab non-structural
197 region that is unique to SARS-CoV-2 and Target 2 is a conserved region of the structural
198 protein envelope E-gene common to all members of the Sarbecovirus sub-genus of
199 coronavirus, which include SARS-CoV-2 and SARS-CoV (8, 9). The cobas assay also includes
200 an internal control for assay performance that has no homology to the coronaviruses.

201 When comparing positive and indeterminate results from repeat-tested with single tested
202 patients, there were no differences in indeterminate Ct values, which is expected as by
203 definition the indeterminate results represent high Ct values. In contrast, the repeat-tested
204 group (N=795) had significantly higher target 2 Ct values (median = 29.1 vs. 27.3, $p<0.001$
205 and frequency of target 2 Ct's above 30 (45.8% vs. 36.9%, $p<0.001$) compared to single-
206 tested patients (N=4,548), indicating lower viral load in the repeat-tested samples (Figure
207 1 and Supplementary Table 4).

208

209 **Analysis of conversion rates of repeat-tested patients**

210 In this study, we classified repeat-tested patients in two groups according to their initial
211 SARS-CoV-2 results: those that were initially positive, for whom repeat testing was most
212 likely intended to ascertain recovery and non-infectiousness, and those that had an initial
213 result of negative, indeterminate, or invalid, in whom persistent clinical suspicion for
214 COVID-19 likely motivated repeat ordering of the test. Supplementary Table 4 shows the
215 different clinical characteristics between repeat-tested and single-tested patients.

216 For the time-dependent analysis of conversion rates, we considered “initially positive”
217 patients with any “Detected” or “Indeterminate” SARS-CoV-2 result obtained during the

218 first calendar day of testing rather than the first positive test, to reduce bias due to
219 nasopharyngeal sampling inadequacy (Table 1). Conversely, patients without a result of
220 “Detected” or “Indeterminate” in the first day were labeled as “initially negative”. Among
221 the 2,413 initially negative repeat-tested patients, 18.6% became positive upon repeat
222 testing on subsequent days (Supplementary Table 5), indicating a negative predictive value
223 of 81.3% (95% CI = 79.7 to 82.8) in this repeat-tested population with the prevalence
224 present at the time of the study.

225 In a separate analysis, we compared the results of the first test with the results from tests
226 repeated the same day (Supplementary Table 5) or repeated any time after the first result
227 (Supplementary Table 6). Among the patients with repeat testing who had initial results of
228 “Invalid” (241), “Not Detected” (2280), or “Indeterminate” (114), 4.2% had ‘Detected’
229 results upon repeat testing in the first day of testing (Supplementary Table 5). This
230 increase in positivity rate most likely results from a false-negative initial test due to pre-
231 analytic factors such as sample inadequacy, incorrect swabbing technique, or stochastic
232 sampling bias from low viral loads in the patient nasopharynx. After the first day of testing,
233 repeating invalid, negative, or indeterminate results on the same day resulted in about
234 0.8% of additional positive results per day, for a total of 18.4% positives that were missed
235 by the first test.

236 Among the 1,371 repeat-tested patients with one or more SARS-CoV-2 results of
237 “Detected”, which can be assumed to be truly infected, only 58.1% were resulted as
238 “Detected” on the initial test (Supplementary Table 5), and only 66.2% were reported as
239 “Detected” on the first day (Table 1). Considering ‘Detected’ and “Indeterminate” as
240 positive, 1,471 repeat-tested patients had one or more SARS-CoV-2 positive results over
241 time; only 61.9% were positive on the initial test and only 69.3% had a positive result on

242 the first day (Table 1). These data provide an estimate of the clinical sensitivity of the assay
243 in the repeat-tested population, and establish a baseline to look at conversion rates from
244 negative to positive.

245 Table 2A shows the number of patients who had an initial result of “Not Detected” on day 1
246 who converted to a SARS-CoV-2 positive status grouped per time after the initial test.

247 Conversely, Table 2B shows rates of conversion to negative for patients with a status of
248 “Detected” on day 1. Supplementary Figure 1 shows the distribution per day after onset of
249 symptoms (**a** and **b**) or after initial testing (**c** to **f**) of conversions from positive to negative
250 (left-side) and from negative to positive (right-side) in the two groups of repeat-tested
251 patients. For this analysis, positive status included “Detected” and “Indeterminate” and
252 negative status included results of “Not Detected” with “Invalid” results excluded. Among
253 the initially positive patients, the unadjusted distributions show a peak of conversion to
254 negative between 30 and 40 days after symptoms or around 20 days after initial testing.
255 Less than 10% of the patients who converted to negative converted before 15 days after
256 onset of symptoms or 10 days after initial testing. In contrast, among the patients with
257 initially negative results who converted to positive, most conversions occurred 10 days or
258 less after onset of symptoms, and in the first 1-3 days after initial testing.

259 Since we cannot be certain about the conversion rates due to a significant proportion of
260 repeat-test patients having insufficient testing performed to detect conversion (right-
261 censoring) we used a Kaplan-Meier approach to estimate the conversion rate by day of
262 testing (Figures 2, 3 and Supplementary Figure 1 **e** to **h**) with the following assumptions:

- 263 1. When there were multiple tests performed per patient in one day, the results
264 were aggregated to the highest result, i.e. Detected > Indeterminate > Not
265 Detected.

- 266 2. For initially positive patients, an event is defined as highest result in a day of “Not
267 Detected”.
- 268 3. Conversely, an event is defined as a conversion from a “Not Detected”, or
269 “Invalid” result at day 1 to “Detected” or “Indeterminate” on subsequent days.
- 270 4. If the last test result was unchanged relative to the first day result, the patient
271 was considered right-censored at that time.
- 272 5. Only the first day and either the censoring day or the event day were used for
273 each patient and indeterminate results were ignored.

274 The results show that the probability of converting from positive to negative in the initially
275 positive, repeat-tested population is minimal until about 15 to 20 days after initial testing
276 and reaches 50% at 28 days (95% CI = 27 to 29 days, Figure 2). In the initially negative
277 repeat-tested population, the risk linearly increases every day with a 25% probability of
278 conversion to positive of 20 days (95% CI = 16 to 23 days, Figure 3).

279 Since lack of conversion could be due to death of the patient, which occurred in about 8%
280 of the repeat-tested population, we performed a competing risk analysis with death as the
281 alternative event, using the *timereg* R package (10), and did not find significant differences
282 in either the positive to negative or the negative to positive Kaplan-Meier cumulative
283 probability of conversion (results not shown).

284 Interestingly, among the repeat-tested patients we have identified 11 patients that
285 converted from an initial SARS-CoV-2 negative result to positive and back to negative over
286 several days. We also identified 49 initially positive patients that became negative and later
287 turned positive again. The time course of SARS-CoV-2 test results for these patients are
288 shown on Supplementary Figure 2.

289

290 **Discussion**

291 Our results from repeat-tested patients can be used to estimate the clinical sensitivity of
292 the SARS-CoV-2 molecular testing in the population of patients that were selected for
293 repeat testing, in contrast to the general population of tested patients. With all likelihood,
294 most repeat testing on initial negative patients was performed either to follow a history of
295 exposure, when the clinical profile did not fit the initial results, or when clinical
296 presentation deteriorated after the initial result. Consistent with this hypothesis, repeat-
297 tested patients were more likely to be older, male and of non-Caucasian race than single
298 tested patients (Supplementary Table 3), consistent with the demographics of COVID-19
299 positive patients (Supplementary Table 2). Importantly, repeat-tested patients had worse
300 outcomes as demonstrated by higher rates of decompensation, intubation, and mortality.
301 Interestingly, repeat-tested patient who converted from positive to negative tended to be
302 younger and present as outpatients, as compared to patients that remained positive, but
303 there were no significant differences in clinical outcomes (Supplementary Table 7). In
304 contrast, repeat-tested patients that remained negative tended to be inpatients, have
305 longer admission duration, and were more likely to be extubated than those who converted
306 to positive (Supplementary Table 8), suggesting that a significant number of repeat-testing
307 in SARS-CoV-2 negative patients was performed in inpatients admitted before the
308 pandemic or for non-COVID-19 reasons. Indeed, repeat-tested patients admitted before
309 March 1st, 2020 were much more likely to have a persistent negative result (71.4%) than
310 those admitted after March 1st, 2020 (39.7%, $p < 0.001$).

311 In the absence of a more sensitive gold-standard, the repeat-tested patients with an
312 eventual positive result can be considered true positives, as the analytical specificity of
313 molecular testing is very high (3, 8, 9, 11, 12). It may be tempting to add all the 9,272
314 single-tested positive patients to the 1,371 repeat-tested positive patients to determine
315 clinical sensitivity. However, we don't know how many of the "Not detected" single-tested
316 patients are false negatives, especially given the high frequency of asymptomatic or mildly
317 symptomatic COVID-19 patients (13–15). Therefore, considering only the positive patients
318 will inflate the estimated clinical sensitivity. Nevertheless, if we consider all negative
319 results (repeated or not) to be true negative (i.e. a specificity of 100%) we can estimate the
320 upper bound of the clinical sensitivity of a first initial result to be 94.6% (95% CI = 94.2-
321 95%). If the test is repeated on the first day to account for nasopharyngeal sampling
322 inadequacy, the upper boundary of the estimated sensitivity with these assumptions would
323 be 95.6% (95% CI=95.2-96%). A lower bound of clinical sensitivity can be estimated by
324 considering the worst case scenario that the same percentage of false negatives identified
325 in repeat-tested patients would apply to the general population. With these assumptions,
326 the clinical sensitivity of the SARS-CoV-2 assay can be estimated to be between 66.2%
327 (95% CI = 63.6 to 68.7) and the above best case estimate of 95.6%.

328 The lower clinical sensitivity of the first day results in the ultimately positive repeat-tested
329 patients suggests several possibilities:

- 330 1. Viral shedding increases over time in a recently infected patient and will
331 eventually cross the detection threshold in subsequent samples. This possibility
332 is suggested by the lower Ct values for target 1 and particularly target 2 on the
333 repeat-tested patients (Supplementary Table 4 and Figure 1) .

334

335 2. A significant number of samples are improperly collected, and repeat testing
336 increases the probability of detection; this is particularly likely in the first day of
337 testing, when suspicion may be high but the initial test results were negative or
338 inconclusive, as shown in Supplementary Table 5.

339 3. Initially tested patients were truly negative and acquired the infection
340 nosocomially after admission.

341 The mean interval between an initial negative test result and the first positive in patients
342 who converted in our study was 9.4 days (95% CI = 8.4 to 10.5 days, N = 335), which is
343 longer than reported by Ai et al, who showed a mean interval time between initial negative
344 to positive RT-PCR results of 5.1 ± 1.5 days with a median of 4 days (N = 15) (4). We have
345 insufficient data to calculate incubation time as only 1.3% of the patients had symptoms
346 after the first test, with a median time between symptoms and testing of 1.3 days. The
347 median interval between start of symptoms and the first test in our study of 4.8 days (95%
348 CI = 4.5 to 5.4 days) is in line with the data from Lauer et al., who calculated a median
349 incubation time of 5.1 days (95% CI = 4.5 to 5.8 days) in patients from China (16).

350 The third possibility of hospital-acquired infection explaining a low rate of initial true
351 negative result is less likely because a) patients who converted from negative to positive
352 had shorter intervals between admission and the first test and shorter duration of
353 admission than those who remained negative (Supplementary Table 9 and b) there were
354 no significant differences between repeat-tested inpatients and outpatients in the average
355 time interval between the initial negative test and the first positive test (results not
356 shown). If there were a large number of inpatients acquiring the infection in the hospital
357 one would expect longer intervals between admission and positivity due to the cohort of
358 patients already admitted before the pandemic, as compared to patients recently admitted

359 with COVID-19. Rather, these data suggest a pattern of repeated ordering in uninfected
360 inpatients with a lower likelihood of conversion.

361 Our analysis of repeat-tested patients with an initial positive result, using the Kaplan-Meier
362 estimator, indicates that conversion to a negative result is unlikely to occur until about 15
363 to 20 days after initial testing or 20 to 30 days after start of symptoms, when the odds ratio
364 significantly increase (Figure 2 and Supplementary Figure 1). Conversely, when a patient is
365 suspected of COVID-19 but the initial test is negative, repeating the test steadily increases
366 the probably of conversion to 'Detected' every day (Figure 3). Repeat testing is especially
367 likely to yield a positive result if the initial test is indeterminate or invalid. For
368 indeterminate results, this likely reflects low levels of the virus in the sample or low viral
369 shedding in the nasopharynx early in the course of the infection. For invalid results, this
370 likely reflects sampling inadequacy, often due to excess mucous in the sample. Our finding
371 of significantly higher Ct in repeat-tested patients as compared to single-tested patients
372 supports this hypothesis.

373 **Limitations of the study**

374 This is an observational study without selection bias for the laboratory data, as all results
375 were included in the analysis. However, the clinical data was restricted to a subset of
376 patients seen at Columbia University Irving Medical Center campuses. Nevertheless, rates
377 of positivity and demographic variables captured in the laboratory dataset were not
378 significantly different between the other campuses, suggesting that the population in the
379 clinical dataset is generally representative of the New York City patients tested for COVID-
380 19. Other limitations of the study of repeat-tested patients include: 1) only 15% of the total
381 patient's tested had repeat testing done and 2) ordering of repeat testing was at the
382 discretion of the health care providers and not performed according to a standard protocol,

383 although test ordering was mostly accomplished through standardized electronic medical
384 record order sets.

385 **Conclusions**

386 Our data suggest that patients with a high clinical suspicion or exposure setting suggestive
387 of COVID-19 should be tested by a molecular SARS-CoV-2 assay and it is appropriate to
388 repeat the test the same day or in subsequent days if the results are initially negative.
389 Conversely, for patients with a positive SARS-CoV-2 molecular assay result, repeating the
390 test before at least 15 days after the first test is unlikely to yield a negative result. Whether
391 repeat positivity represents active infection or detection of nonviable viral RNA is
392 unknown. Further studies are needed to develop predictive models of the course and
393 outcomes of COVID-19 using well-curated demographic, clinical, and laboratory datasets.

394

395

396 **Acknowledgments:**

397 We would like to acknowledge the contributions of all the dedicated medical technologists
398 and laboratory technicians who performed testing at NYP laboratories, the efforts of the
399 NYP Laboratory Information Team, in particular Kelvin Espinal, Sarah Russell, Dennis
400 Camp, Yingzhe Kuang, and Bulent Oral for designing queries and providing data extracts,
401 and the volunteers who helped gather data from electronic medical records for the COVID-
402 19 CARE database.

403 *Funding:* This research received no specific grant from any funding agency in the public,
404 commercial, or not-for-profit sectors.

405 *Potential conflicts of interest* All authors have no conflicts.

406

407

408 **References**

409 1. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, Hu Y, Tao Z-W, Tian J-H, Pei Y-Y, Yuan
410 M-L, Zhang Y-L, Dai F-H, Liu Y, Wang Q-M, Zheng J-J, Xu L, Holmes EC, Zhang Y-Z. 2020.
411 A new coronavirus associated with human respiratory disease in China. 7798. Nature
412 579:265–269.

413 2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan
414 F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W. 2020. A Novel Coronavirus from Patients
415 with Pneumonia in China, 2019. N Engl J Med 382:727–733.

416 3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H,
417 Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. 2020. Clinical course and risk factors for
418 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
419 study. Lancet 395:1054–1062.

420 4. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. 2020. Correlation of Chest
421 CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of
422 1014 Cases. Radiology 200642.

423 5. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. 2020. Chest CT for Typical 2019-nCoV
424 Pneumonia: Relationship to Negative RT-PCR Testing. Radiology 200343.

- 425 6. Benjamini Y, Hochberg Y. 1995. Controlling the False Discovery Rate: A Practical and
426 Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B*
427 (Methodological) 57:289–300.
- 428 7. R Core Team. 2017. R: A Language and Environment for Statistical Computing.
- 429 8. Pfefferle S, Reucher S, Nörz D, Lütgehetmann M. 2020. Evaluation of a quantitative RT-
430 PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high
431 throughput system. *Euro Surveill* 25.
- 432 9. Smithgall MC, Scherberkova I, Whittier S, Green DA. 2020. Comparison of Cepheid Xpert
433 Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2.
434 *bioRxiv* 2020.04.22.055327.
- 435 10. Scheike TH, Zhang M-J. 2011. Analyzing Competing Risk Data Using the R *timereg*
436 Package. 1. *Journal of Statistical Software* 38:1–15.
- 437 11. Cordes AK, Heim A. 2020. Rapid random access detection of the novel SARS-
438 coronavirus-2 (SARS-CoV-2, previously 2019-nCoV) using an open access protocol for
439 the Panther Fusion. *J Clin Virol* 125:104305.
- 440 12. Zhen W, Smith E, Manji R, Schron D, Berry GJ. 2020. Clinical Evaluation of Three
441 Sample-To-Answer Platforms for the Detection of SARS-CoV-2. *J Clin Microbiol*.
- 442 13. Lai C-C, Liu YH, Wang C-Y, Wang Y-H, Hsueh S-C, Yen M-Y, Ko W-C, Hsueh P-R. 2020.
443 Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe
444 acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. *J Microbiol*
445 *Immunol Infect*.

- 446 14. Li C, Ji F, Wang L, Wang L, Hao J, Dai M, Liu Y, Pan X, Fu J, Li L, Yang G, Yang J, Yan X, Gu
447 B. Early Release - Asymptomatic and Human-to-Human Transmission of SARS-CoV-2 in
448 a 2-Family Cluster, Xuzhou, China - Volume 26, Number 7—July 2020 - Emerging
449 Infectious Diseases journal - CDC.
- 450 15. Wang Y, Liu Y, Liu L, Wang X, Luo N, Li L. Clinical Outcomes in 55 Patients With Severe
451 Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital
452 Admission in Shenzhen, China. *J Infect Dis.*
- 453 16. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler
454 J. 2020. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly
455 Reported Confirmed Cases: Estimation and Application. *Ann Intern Med.*
- 456
- 457
- 458
- 459

460 **Tables**

461 Table 1: Number of SARS-CoV-2 molecular test results over the course of repeat testing,
462 grouped by the highest test result on day 1.

Highest Result	Invalid	Not Detected	Indeterminate	Detected	Total
Any Day —>	(N=1)	(N=1960)	(N=100)	(N=1371)	(N=3432)
Highest Day 1					p value <0.001 ¹
Result					
Invalid	1 (100%)	80 (4.1%)	3 (3.0%)	79 (5.8%)	163 (4.7%)
Not Detected	0 (0.0%)	1880 (95.9%)	35 (35.0%)	335 (24.4%)	2250 (65.6%)
Indeterminate	0 (0.0%)	0 (0.0%)	62 (62.0%)	50 (3.6%)	112 (3.3%)
Detected	0 (0.0%)	0 (0.0%)	0 (0.0%)	907 (66.2%)	907 (26.4%)

463 1. Pearson's Chi-squared test (adjusted for multiple comparisons)

464

465

466 Table 2: Distribution of repeat tests per day after a first day result of “Not Detected” or
 467 “Indeterminate” (A) or after a first day result of “Detected” (B).

	Not Detected	Indeterminate	Detected	Total
Day of testing				
A. Highest day 1 result of ‘Not Detected’ or ‘Indeterminate’				
1	1995 (95.2%)	100 (4.8%)	0 (0.0%)	2095
2	505 (75.6%)	38 (5.7%)	125 (18.7%)	668
3-6	568 (84.6%)	7 (1.0%)	96 (14.3%)	671
7-9	322 (89.4%)	5 (1.4%)	33 (9.2%)	360
10-16	464 (86.6%)	5 (0.9%)	67 (12.5%)	536
> 16	562 (85.3%)	7 (1.1%)	90 (13.7%)	659
B. Highest day 1 result of ‘Detected’				
1	0 (0.0%)	0 (0.0%)	754 (100%)	754
2	5 (13.5%)	2 (5.4%)	30 (81.1%)	37
3-6	7 (14.3%)	1 (2.0%)	41 (83.7%)	49
7-9	12 (16.7%)	6 (8.3%)	54 (75.0%)	72
10-16	43 (20.5%)	19 (9.0%)	148 (70.5%)	210
16-20	196 (88.7%)	2 (0.9%)	23 (10.4%)	221
21-30	227 (84.4%)	0 (0.0%)	42 (15.6%)	269
>30	139 (82.2%)	5 (3.0%)	25 (14.8%)	169

469 **Figure Legends**

470 Figure 1: Density distribution of cobas SARS-2-CoV2 Target 2 Ct values in repeat-tested
471 vs. single-tested patients. Top panel: Ct values from results reported as “Intermediate”;
472 bottom panel: Ct values from results reported as “Detected”.

473

474 Figure 2: Kaplan-Meier estimate of conversion from an initially positive SARS-CoV-2 status
475 on day 1 to a subsequent negative result.

476

477 Figure 3: Kaplan-Meier estimate of conversion rate from initially negative SARS-CoV-2
478 status on day 1 to a subsequent positive result.

479

480

481

Figure 1: Density distribution of cobas SARS-2-CoV2 Target 2 Ct in repeat-tested vs. single-tested patients. Top panel: Ct values from results reported as “intermediate”; bottom panel: Ct values from results reported as “detected”.




Figure 2: Kaplan-Meier estimate of conversion from an initially positive SARS-CoV-2 status on day 1 to a subsequent negative result.







Figure 3: Kaplan-Meier estimate of conversion rate from initially negative SARS-CoV-2 status on day 1 to a subsequent positive result.




Supplementary Figure 1: Conversion distributions for repeat-tested patients with initial SARS-CoV-2 negative (**a**, **c**, **e**, and **g**) and positive (**b**, **d**, **f**, and **h**) results. For the analyses in **a** to **d** only the first conversion events (i.e. negative to positive - **a** and **c** - or positive to negative - **b** and **d**) were considered. **N** represents the total numbers of patients analyzed. The distributions in **a** to **d** are represented by density-adjusted histograms (in grey bars), kernel probability density lines (in blue), unadjusted cumulative distributions (red line) and Kaplan-Meier hazard rates (green); the timing of individual results are represented by the black marks along the x-axis. For the Kaplan Meier estimated hazard rates (**e** to **h**), in addition to the conversion events, patients were considered censored at the time of the last unchanged result were included and the number of patients at risk for conversion at each time point are shown in **g** and **h**.



Supplementary Figure 2: SARS-CoV-2 results from repeat-tested patients that converted from negative to positive and back to negative (**A**) or from positive to negative and back to positive (**B**). SARS-CoV-2 negative results are represented by blue dots and positive results are in red, plotted on a time scale from the date of the first test





Supplementary Tables

Supplementary Table 1: Numbers of unique patients in the Columbia Clinical COVID-19 dataset, NYP Laboratory SARS-CoV-2 Testing dataset, and the merged dataset.

Unique Patients	Merged dataset	Laboratory dataset only	Clinical dataset only
Total	1588	20750	36
SARS-CoV-2 Positive	990	9653	11
Repeat-tested	275	3157	0
With symptoms	529	0	8
Deceased	84	0	0
SARS-CoV-2 Tests			
Total	2023	25354	2
SARS-CoV-2 Positive	1266	11454	4
Repeat-tested	710	7761	0
With symptoms	707	0	1
Deceased	115	0	0

Supplementary Table 2: Patient characteristics, grouped by highest SARS-2-CoV2 result in each patient. **Negative** indicates a result of “Not Detected” and **Positive** includes results reported as “Detected” or “Indeterminate”. Time-dependent clinical factors, such as age group, symptom start to test interval, and encounter type at time of test order, are counted at the time of the first test.

	Negative (N=11352)	Positive (N=10920)	Total (N=22272)	p value
Gender at birth				< 0.001 ¹
Female	7045 (62.1%)	5061 (46.4%)	12106 (54.4%)	
Male	4291 (37.8%)	5851 (53.6%)	10142 (45.5%)	
Unknown	16 (0.1%)	7 (0.1%)	23 (0.1%)	
N	11352	10919	22271	
Age at order				< 0.001 ²
Median	42.9	61.5	54.4	
Mean (sd)	46.5 (23.0)	60.0 (19.3)	53.1 (22.3)	
Q1, Q3	31.4, 64.0	46.5, 74.5	35.5, 70.4	
Range	0.0 - 120.3	0.0 - 144.7	0.0 - 144.7	
N	11352	10920	22272	
Age group (y)				< 0.001 ³
0-19	1069 (9.4%)	155 (1.4%)	1224 (5.5%)	
20-44	4912 (43.3%)	2387 (21.9%)	7299 (32.8%)	
45-54	1255 (11.1%)	1533 (14.0%)	2788 (12.5%)	
55-64	1389 (12.2%)	2148 (19.7%)	3537 (15.9%)	
65-74	1236 (10.9%)	2065 (18.9%)	3301 (14.8%)	
75-84	868 (7.7%)	1588 (14.5%)	2456 (11.0%)	
>=85	616 (5.4%)	1044 (9.6%)	1660 (7.5%)	
N	11345	10920	22265	
Ethnicity				<(0.001 ¹
Hispanic/Latino	154 (26.3%)	308 (31.0%)	462 (29.3%)	
Not Hispanic/Latino	311 (53.2%)	409 (41.2%)	720 (45.7%)	
Not Specified	120 (20.5%)	275 (27.7%)	395 (25.0%)	
N	585	992	1577	
Race				< 0.001 ¹
Asian	752 (6.6%)	531 (4.9%)	1283 (5.8%)	
Black or African American	1629 (14.3%)	1833 (16.8%)	3462 (15.5%)	
Caucasian	3586 (31.6%)	2356 (21.6%)	5942 (26.7%)	

	Negative (N=11352)	Positive (N=10920)	Total (N=22272)	p value
Declined	1593 (14.0%)	1308 (12.0%)	2901 (13.0%)	
Other	1769 (15.6%)	2287 (20.9%)	4056 (18.2%)	
Pacific Islander	20 (0.2%)	25 (0.2%)	45 (0.2%)	
Unavailable	2003 (17.6%)	2580 (23.6%)	4583 (20.6%)	
N	11352	10920	22272	
Highest level of care				0.025 ¹
Admitted	229 (41.4%)	305 (35.1%)	534 (37.6%)	
Discharged from ED	58 (10.5%)	71 (8.2%)	129 (9.1%)	
ICU-level Care	69 (12.5%)	119 (13.7%)	188 (13.2%)	
Outpatient	197 (35.6%)	373 (43.0%)	570 (40.1%)	
N	553	868	1421	
Encounter type at order				< 0.001 ¹
Emergency	2706 (23.8%)	4748 (43.5%)	7454 (33.5%)	
Inpatient	3827 (33.7%)	2555 (23.4%)	6382 (28.7%)	
Outpatient	4819 (42.5%)	3617 (33.1%)	8436 (37.9%)	
N	11352	10920	22272	
Location at order				< 0.001 ¹
Allen Hospital	448 (3.9%)	845 (7.7%)	1293 (5.8%)	
Columbia	4505 (39.7%)	3924 (35.9%)	8429 (37.8%)	
Columbia Outreach	509 (4.5%)	743 (6.8%)	1252 (5.6%)	
Lower Manhattan	633 (5.6%)	437 (4.0%)	1070 (4.8%)	
Queens	1588 (14.0%)	2555 (23.4%)	4143 (18.6%)	
Weill Cornell	3518 (31.0%)	2388 (21.9%)	5906 (26.5%)	
Westchester	151 (1.3%)	28 (0.3%)	179 (0.8%)	
N	11352	10920	22272	
Number of admissions				0.008 ²
Median	1.0	0.0	0.0	
Mean (sd)	0.5 (0.5)	0.5 (0.5)	0.5 (0.5)	
Q1, Q3	0.0, 1.0	0.0, 1.0	0.0, 1.0	
Range	0.0 - 2.0	0.0 - 2.0	0.0 - 2.0	
N	584	995	1579	
Admission duration (d)				0.046 ²

	Negative (N=11352)	Positive (N=10920)	Total (N=22272)	p value
Median	1.0	0.6	0.7	
Mean (sd)	5.7 (13.9)	4.5 (8.1)	4.9 (10.6)	
Q1, Q3	0.4, 4.0	0.3, 4.9	0.3, 4.5	
Range	0.0 - 139.0	0.0 - 82.2	0.0 - 139.0	
N	584	995	1579	
Admission 1 to test 1 (d)				< 0.001 ²
Median	0.4	0.2	0.3	
Mean (sd)	3.0 (11.4)	0.7 (2.6)	1.6 (7.4)	
Q1, Q3	0.2, 1.1	0.1, 0.6	0.2, 0.9	
Range	-13.9 - 133.1	0.0 - 55.4	-13.9 - 133.1	
N	555	924	1479	
Admission 2 to test 1 (d)				0.999 ²
Median	-7.9	-8.5	-8.3	
Mean (sd)	-9.4 (9.3)	-9.4 (7.5)	-9.4 (8.1)	
Q1, Q3	-16.9, -0.9	-14.3, -2.1	-15.4, -1.5	
Range	-29.0 - 1.2	-25.9 - 0.3	-29.0 - 1.2	
N	34	70	104	
Primary Outcome				< 0.001 ¹
Deceased/Discharged to Hospice	29 (5.0%)	72 (7.2%)	101 (6.4%)	
Discharged (not death)	542 (92.8%)	865 (86.9%)	1407 (89.1%)	
Intubated (still admitted)	1 (0.2%)	44 (4.4%)	45 (2.8%)	
Still admitted (not intubated)	12 (2.1%)	14 (1.4%)	26 (1.6%)	
N	584	995	1579	
Deceased				0.048 ¹
No	562 (96.2%)	933 (93.8%)	1495 (94.7%)	
Yes	22 (3.8%)	62 (6.2%)	84 (5.3%)	
N	584	995	1579	
Symptomatic				0.004 ¹
No	2 (6.9%)	10 (1.8%)	12 (2.0%)	
Unknown	6 (20.7%)	36 (6.4%)	42 (7.1%)	
Yes	21 (72.4%)	514 (91.8%)	535 (90.8%)	
N	29	560	589	
Symptoms start to death (d)				0.828 ²
Median	11.6	14.0	13.7	
Mean (sd)	11.6 (NA)	14.8 (9.3)	14.7 (9.2)	
Q1, Q3	11.6, 11.6	6.9, 19.2	7.0, 19.1	
Range	11.6 - 11.6	1.6 - 39.6	1.6 - 39.6	
N	1	46	47	

	Negative (N=11352)	Positive (N=10920)	Total (N=22272)	p value
Any fever				0.936 ¹
No	5 (23.8%)	133 (25.4%)	138 (25.4%)	
Yes	16 (76.2%)	390 (74.6%)	406 (74.6%)	
N	21	523	544	
Intubated				0.026 ¹
No	543 (93.0%)	889 (89.3%)	1432 (90.7%)	
Yes	41 (7.0%)	106 (10.7%)	147 (9.3%)	
N	584	995	1579	
Extubated				0.046 ¹
No	557 (95.4%)	969 (97.4%)	1526 (96.6%)	
Yes	27 (4.6%)	26 (2.6%)	53 (3.4%)	
N	584	995	1579	
Symptoms start to intubation (d)				0.152 ²
Median	7.0	8.0	8.0	
Mean (sd)	16.3 (19.7)	9.2 (7.3)	9.4 (7.9)	
Q1, Q3	5.0, 23.0	4.2, 11.0	4.0, 11.0	
Range	3.0 - 39.0	-3.0 - 39.0	-3.0 - 39.0	
N	3	90	93	
Intubation duration (d)				0.069 ²
Median	3.0	6.0	5.0	
Mean (sd)	4.2 (4.7)	6.9 (4.7)	5.4 (4.9)	
Q1, Q3	1.2, 5.0	4.5, 9.5	2.0, 8.0	
Range	-3.0 - 20.0	0.0 - 20.0	-3.0 - 20.0	
N	26	23	49	
Decompensated				0.005 ¹
No	535 (91.6%)	862 (86.6%)	1397 (88.5%)	
Yes	49 (8.4%)	133 (13.4%)	182 (11.5%)	
N	584	995	1579	
Symptoms start to decompensation (d)				
Median	9.0	8.0	8.0	
Mean (sd)	15.0 (16.3)	9.9 (8.2)	10.1 (8.5)	
Q1, Q3	6.0, 18.0	4.0, 13.0	4.0, 13.0	
Range	3.0 - 39.0	-3.0 - 39.0	-3.0 - 39.0	
N	4	108	112	
Symptoms start to first test (d)				
Median	4.4	4.7	4.7	
Mean (sd)	6.9 (13.7)	6.9 (17.0)	6.9 (16.9)	
Q1, Q3	2.5, 12.5	2.7, 7.9	2.7, 7.9	

	Negative (N=11352)	Positive (N=10920)	Total (N=22272)	p value
Range	-29.4 - 51.1	-4.3 - 366.8	-29.4 - 366.8	
N	21	508	529	
Number of tests				< 0.001 ²
Median	1.0	1.0	1.0	
Mean (sd)	1.2 (0.6)	1.2 (0.7)	1.2 (0.7)	
Q1, Q3	1.0, 1.0	1.0, 1.0	1.0, 1.0	
Range	1.0 - 8.0	1.0 - 41.0	1.0 - 41.0	
N	11352	10920	22272	
Number of positive results per patient				
Median	0.0	1.0	0.0	
Mean (sd)	0.0 (0.0)	1.0 (0.4)	0.5 (0.6)	
Q1, Q3	0.0, 0.0	1.0, 1.0	0.0, 1.0	
Range	0.0 - 0.0	0.0 - 20.0	0.0 - 20.0	
N	11352	10920	22272	
Number of positive results per patient (Indeterminate included)				
Median	0.0	1.0	0.0	
Mean (sd)	0.0 (0.0)	1.1 (0.4)	0.5 (0.6)	
Q1, Q3	0.0, 0.0	1.0, 1.0	0.0, 1.0	
Range	0.0 - 0.0	1.0 - 20.0	0.0 - 20.0	
N	11352	10920	22272	

1. Pearson's Chi-squared test (adjusted for multiple comparisons)
2. Linear Model ANOVA (adjusted for multiple comparisons)
3. Trend test for ordinal variables (adjusted for multiple comparisons)

Supplementary Table 3: Patient characteristics comparing repeat-tested with single-tested patients.

	Repeat (N=3432)	Single (N=18906)	Total (N=22338)	p value
Gender at birth				<0.001 ¹
Female	1644 (47.9%)	10503 (55.6%)	12147 (54.4%)	
Male	1787 (52.1%)	8380 (44.3%)	10167 (45.5%)	
Unknown	1 (0.0%)	22 (0.1%)	23 (0.1%)	
N	3432	18905	22337	
Age at order				<0.001 ²
Median	59.7	53.4	54.4	
Mean (sd)	55.5 (23.3)	52.7 (22.1)	53.1 (22.3)	
Q1, Q3	39.6, 72.3	35.0, 70.0	35.5, 70.4	
Range	0.0 - 120.3	0.0 - 144.7	0.0 - 144.7	
N	3432	18906	22338	
Age group (y)				<0.001 ³
0-19	278 (8.1%)	949 (5.0%)	1227 (5.5%)	
20-44	751 (21.9%)	6569 (34.8%)	7320 (32.8%)	
45-54	413 (12.0%)	2384 (12.6%)	2797 (12.5%)	
55-64	604 (17.6%)	2943 (15.6%)	3547 (15.9%)	
65-74	673 (19.6%)	2639 (14.0%)	3312 (14.8%)	
75-84	450 (13.1%)	2017 (10.7%)	2467 (11.0%)	
>=85	259 (7.6%)	1402 (7.4%)	1661 (7.4%)	
N	3428	18903	22331	
Ethnicity				0.231 ¹
Hispanic/Latino	92 (33.5%)	371 (28.3%)	463 (29.2%)	
Not Hispanic/Latino	121 (44.0%)	602 (46.0%)	723 (45.6%)	
Not Specified	62 (22.5%)	337 (25.7%)	399 (25.2%)	
N	275	1310	1585	
Race				< 0.001 ¹
Asian	220 (6.4%)	1065 (5.6%)	1285 (5.8%)	
Black or African American	620 (18.1%)	2856 (15.1%)	3476 (15.6%)	
Caucasian	963 (28.1%)	5006 (26.5%)	5969 (26.7%)	
Declined	476 (13.9%)	2432 (12.9%)	2908 (13.0%)	
Other	633 (18.4%)	3431 (18.1%)	4064 (18.2%)	
Pacific Islander	12 (0.3%)	34 (0.2%)	46 (0.2%)	
Unavailable	508 (14.8%)	4082 (21.6%)	4590 (20.5%)	
N	3432	18906	22338	
Highest level of care				<0.001 ¹
Admitted	120 (45.1%)	414 (35.6%)	534 (37.4%)	
Discharged from ED	16 (6.0%)	113 (9.7%)	129 (9.0%)	

ICU-level Care	79 (29.7%)	109 (9.4%)	188 (13.2%)	
Outpatient	51 (19.2%)	526 (45.3%)	577 (40.4%)	
N	266	1162	1428	
Encounter type at order				<0.001 ¹
Emergency	1273 (37.1%)	6197 (32.8%)	7470 (33.4%)	
Inpatient	1400 (40.8%)	4998 (26.4%)	6398 (28.6%)	
Outpatient	759 (22.1%)	7711 (40.8%)	8470 (37.9%)	
N	3432	18906	22338	
Location at order				<0.001 ¹
Allen Hospital	204 (5.9%)	1099 (5.8%)	1303 (5.8%)	
Columbia	1434 (41.8%)	7031 (37.2%)	8465 (37.9%)	
Columbia Outreach	116 (3.4%)	1144 (6.1%)	1260 (5.6%)	
Lower Manhattan	161 (4.7%)	911 (4.8%)	1072 (4.8%)	
NYHQ	495 (14.4%)	3654 (19.3%)	4149 (18.6%)	
Weill Cornell	973 (28.4%)	4936 (26.1%)	5909 (26.5%)	
WESTCHESTER	49 (1.4%)	131 (0.7%)	180 (0.8%)	
N	3432	18906	22338	
Number of admissions				<0.001 ²
Median	1.0	0.0	0.0	
Mean (sd)	0.9 (0.6)	0.4 (0.5)	0.5 (0.5)	
Q1, Q3	0.0, 1.0	0.0, 1.0	0.0, 1.0	
Range	0.0 - 2.0	0.0 - 1.0	0.0 - 2.0	
N	275	1312	1587	
Admission duration (d)				<0.001 ²
Median	5.8	0.6	0.7	
Mean (sd)	11.6 (13.5)	3.5 (9.3)	4.9 (10.6)	
Q1, Q3	1.0, 19.4	0.3, 2.9	0.3, 4.4	
Range	0.0 - 83.5	0.0 - 139.0	0.0 - 139.0	
N	275	1312	1587	
Admission 1 to test 1 (d)				0.112 ²
Median	0.4	0.3	0.3	
Mean (sd)	2.3 (6.7)	1.4 (7.5)	1.6 (7.3)	
Q1, Q3	0.2, 1.1	0.2, 0.9	0.2, 0.9	
Range	-13.9 - 56.1	0.0 - 133.1	-13.9 - 133.1	
N	268	1218	1486	
Admission 2 to test 1 (d)				<0.001 ²
Median	-9.0	0.1	-8.3	
Mean (sd)	-10.6 (7.8)	-2.6 (5.9)	-9.4 (8.1)	
Q1, Q3	-15.8, -4.0	-1.2, 0.2	-15.4, -1.5	
Range	-29.0 - 0.5	-19.1 - 1.2	-29.0 - 1.2	

N	88	16	104	
Primary Outcome				<0.001 ¹
Deceased/Discharged to Hospice	27 (9.8%)	74 (5.6%)	101 (6.4%)	
Discharged (not death)	196 (71.3%)	1219 (92.9%)	1415 (89.2%)	
Intubated (still admitted)	31 (11.3%)	14 (1.1%)	45 (2.8%)	
Still admitted (not intubated)	21 (7.6%)	5 (0.4%)	26 (1.6%)	
N	275	1312	1587	
Deceased				0.038 ¹
No	253 (92.0%)	1250 (95.3%)	1503 (94.7%)	
Yes	22 (8.0%)	62 (4.7%)	84 (5.3%)	
N	275	1312	1587	
Symptomatic				0.035 ¹
No	4 (3.8%)	8 (1.6%)	12 (2.0%)	
Unknown	2 (1.9%)	42 (8.6%)	44 (7.4%)	
Yes	99 (94.3%)	436 (89.7%)	535 (90.5%)	
N	105	486	591	
Symptoms start to death (d)				0.320 ²
Median	12.3	14.3	13.7	
Mean (sd)	17.4 (11.9)	14.0 (8.4)	14.7 (9.2)	
Q1, Q3	9.8, 25.6	6.9, 19.1	7.0, 19.1	
Range	3.3 - 39.6	1.6 - 38.3	1.6 - 39.6	
N	10	37	47	
Any fever				0.925 ¹
No	25 (25.0%)	113 (25.5%)	138 (25.4%)	
Yes	75 (75.0%)	331 (74.5%)	406 (74.6%)	
N	100	444	544	
Intubated				<0.001 ¹
No	208 (75.6%)	1232 (93.9%)	1440 (90.7%)	
Yes	67 (24.4%)	80 (6.1%)	147 (9.3%)	
N	275	1312	1587	
Extubated				<0.001 ¹
No	251 (91.3%)	1283 (97.8%)	1534 (96.7%)	
Yes	24 (8.7%)	29 (2.2%)	53 (3.3%)	
N	275	1312	1587	
Symptoms start to intubation (d)				
Median	9.0	7.0	8.0	
Mean (sd)	10.9 (7.0)	8.3 (8.4)	9.4 (7.9)	
Q1, Q3	7.0, 14.0	3.0, 10.2	4.0, 11.0	
Range	0.0 - 30.0	-3.0 - 39.0	-3.0 - 39.0	

N	41	52	93	
Intubation duration (d)				0.297 ²
Median	5.0	4.5	5.0	
Mean (sd)	6.3 (5.5)	4.7 (4.2)	5.4 (4.9)	
Q1, Q3	2.5, 8.5	1.0, 7.8	2.0, 8.0	
Range	1.0 - 20.0	-3.0 - 13.0	-3.0 - 20.0	
N	23	26	49	
Decompensated				<0.001 ¹
No	199 (72.4%)	1206 (91.9%)	1405 (88.5%)	
Yes	76 (27.6%)	106 (8.1%)	182 (11.5%)	
N	275	1312	1587	
Symptoms start to decompensation (d)				
Median	9.0	7.0	8.0	
Mean (sd)	11.7 (8.3)	9.0 (8.6)	10.1 (8.5)	
Q1, Q3	7.0, 15.0	3.5, 11.0	4.0, 13.0	
Range	0.0 - 39.0	-3.0 - 39.0	-3.0 - 39.0	
N	45	67	112	
Symptoms start to first test (d)				
Median	5.3	4.6	4.7	
Mean (sd)	9.8 (36.8)	6.3 (6.4)	6.9 (16.9)	
Q1, Q3	2.1, 8.3	2.8, 7.8	2.7, 7.9	
Range	-4.3 - 366.8	-29.4 - 60.8	-29.4 - 366.8	
N	98	431	529	
Number of tests				<0.001 ²
Median	2.0	1.0	1.0	
Mean (sd)	2.5 (1.1)	1.0 (0.0)	1.2 (0.7)	
Q1, Q3	2.0, 3.0	1.0, 1.0	1.0, 1.0	
Range	1.0 - 41.0	1.0 - 1.0	1.0 - 41.0	
N	3432	18906	22338	
Number of positive results per patient				
Median	0.0	0.0	0.0	
Mean (sd)	0.6 (0.9)	0.5 (0.5)	0.5 (0.6)	
Q1, Q3	0.0, 1.0	0.0, 1.0	0.0, 1.0	
Range	0.0 - 20.0	0.0 - 1.0	0.0 - 20.0	
N	3432	18906	22338	
Number of positive results per patient (indeterminate included)				
Median	0.0	0.0	0.0	
Mean (sd)	0.7 (1.0)	0.5 (0.5)	0.5 (0.6)	
Q1, Q3	0.0, 1.0	0.0, 1.0	0.0, 1.0	
Range	0.0 - 20.0	0.0 - 1.0	0.0 - 20.0	

N	3432	18906	22338	1.
Highest SARS-CoV-2 Result				<0.001 ¹
Invalid	1 (0.0%)	65 (0.3%)	66 (0.3%)	
Not Detected	1960 (57.1%)	9392 (49.7%)	11352 (50.8%)	
Indeterminate	100 (2.9%)	177 (0.9%)	277 (1.2%)	
Detected	1371 (39.9%)	9272 (49.0%)	10643 (47.6%)	
N	3432	18906	22338	

Pearson's Chi-squared test (adjusted for multiple comparisons)

2. Linear Model ANOVA (adjusted for multiple comparisons)
3. Trend test for ordinal variables (adjusted for multiple comparisons)

Supplementary Table 4: SARS-CoV-2 molecular tests in repeat-tested vs. single-tested patients. N represents the number of tests in each category.

	Repeat (N=8471)	Single (N=18906)	Total (N=27377)	p value
Method				<0.001 ¹
cobas 6800	5841 (69.0%)	13354 (70.6%)	19195 (70.1%)	
Infiniti	1900 (22.4%)	4054 (21.4%)	5954 (21.7%)	
GeneXpert	91 (1.1%)	174 (0.9%)	265 (1.0%)	
ID Now	9 (0.1%)	44 (0.2%)	53 (0.2%)	
Panther Fusion	11 (0.1%)	15 (0.1%)	26 (0.1%)	
QuantStudio	571 (6.7%)	1224 (6.5%)	1795 (6.6%)	
7500 Fast	48 (0.6%)	41 (0.2%)	89 (0.3%)	
N	8471	18906	27377	
cobas				<0.001 ²
No	8471 (100.0%)	18906 (100.0%)	27377 (100.0%)	
N	8471	18906	27377	
Initial result				<0.001 ¹
Invalid	554 (6.5%)	65 (0.3%)	619 (2.3%)	
Not Detected	5613 (66.3%)	9392 (49.7%)	15005 (54.8%)	
Indeterminate	265 (3.1%)	177 (0.9%)	442 (1.6%)	
Detected	2039 (24.1%)	9272 (49.0%)	11311 (41.3%)	
N	8471	18906	27377	
Highest result on day 1				<0.001 ¹
Invalid	367 (4.3%)	65 (0.3%)	432 (1.6%)	
Not Detected	5501 (64.9%)	9392 (49.7%)	14893 (54.4%)	
Indeterminate	267 (3.2%)	177 (0.9%)	444 (1.6%)	
Detected	2336 (27.6%)	9272 (49.0%)	11608 (42.4%)	
N	8471	18906	27377	
Highest result any day				<0.001 ¹
Invalid	2 (0.0%)	65 (0.3%)	67 (0.2%)	
Not Detected	4775 (56.4%)	9392 (49.7%)	14167 (51.7%)	
Indeterminate	246 (2.9%)	177 (0.9%)	423 (1.5%)	
Detected	3448 (40.7%)	9272 (49.0%)	12720 (46.5%)	
N	8471	18906	27377	
Control Ct				<0.001 ³
Median	34.0	33.9	33.9	
Mean (sd)	34.2 (1.1)	34.1 (1.0)	34.1 (1.0)	
Q1, Q3	33.5, 34.7	33.4, 34.5	33.5, 34.6	
Range	32.5 - 41.2	32.4 - 40.5	32.4 - 41.2	
N	2144	7262	9406	
Target 1 Ct				0.036 ³

	Repeat (N=8471)	Single (N=18906)	Total (N=27377)	p value
Median	27.5	26.6	26.7	
Mean (sd)	26.7 (5.5)	26.2 (5.5)	26.3 (5.5)	
Q1, Q3	22.3, 31.4	21.8, 31.0	21.9, 31.0	
Range	13.3 - 36.8	12.4 - 38.0	12.4 - 38.0	
N	744	4533	5277	
Target 2 Ct				<0.001 ³
Median	29.1	27.3	27.6	
Mean (sd)	28.5 (6.5)	27.3 (6.1)	27.5 (6.2)	
Q1, Q3	23.2, 34.0	22.3, 32.5	22.5, 32.7	
Range	13.7 - 39.8	12.9 - 43.7	12.9 - 43.7	
N	795	4548	5343	
Target 2 Ct > 30				<0.001 ¹
FALSE	431 (54.2%)	2869 (63.1%)	3300 (61.8%)	
TRUE	364 (45.8%)	1679 (36.9%)	2043 (38.2%)	
N	795	4548	5343	

1. Pearson's Chi-squared test (adjusted for multiple comparisons)
2. Chi-squared test for given probabilities (adjusted for multiple comparisons)
3. Linear Model ANOVA (adjusted for multiple comparisons)

Supplementary Table 5: Number of SARS-CoV-2 molecular test results of repeat-tested patients on day 1 of testing. Rows represent the initial test result and columns the highest test result on day 1.

Highest First Day Result —>	Invalid (N=163)	Not Detected (N=2250)	Indeterminate (N=112)	Detected (N=907)	Total (N=3432)
Initial Result					p value < 0.001 ¹
Invalid	163 (100%)	32 (1.4%)	1 (0.9%)	45 (5.0%)	241 (7.0%)
Not Detected	0 (0.0%)	2218 (98.6%)	13 (11.6%)	49 (5.4%)	2280 (66.4%)
Indeterminate	0 (0.0%)	0 (0.0%)	98 (87.5%)	16 (1.8%)	114 (3.3%)
Detected	0 (0.0%)	0 (0.0%)	0 (0.0%)	797 (87.9%)	797 (23.2%)

1. Pearson's Chi-squared test (adjusted for multiple comparisons)

Supplementary Table 6: Number of SARS-CoV-2 molecular test results over the course of repeat testing, grouped by the initial test result on day 1.

Highest Result Any Day —>	Invalid (N=1)	Not Detected (N=1960)	Indeterminate (N=100)	Detected (N=1371)	Total (N=3432)
Initial Result					p-value < 0.001 ¹
Invalid	1 (100%)	110 (5.6%)	3 (3.0%)	127 (9.3%)	241 (7.0%)
Not Detected	0 (0.0%)	1850 (94.4%)	45 (45.0%)	385 (28.1%)	2280 (66.4%)
Indeterminate	0 (0.0%)	0 (0.0%)	52 (52.0%)	62 (4.5%)	114 (3.3%)
Detected	0 (0.0%)	0 (0.0%)	0 (0.0%)	797 (58.1%)	797 (23.2%)

1. Pearson's Chi-squared test (adjusted for multiple comparisons)

Supplementary Table 7: Characteristics of initially positive repeat-tested patients comparing those that converted from positive to negative (Pos2neg) with those that remained positive (Unchanged pos).

	Pos2neg (N=330)	Unchanged pos (N=413)	Total (N=743)	p value
Gender at birth				0.599 ¹
Female	138 (41.8%)	162 (39.2%)	300 (40.4%)	
Male	192 (58.2%)	251 (60.8%)	443 (59.6%)	
N	330	413	743	
Age at order				0.014 ²
Median	58.6	62.6	61.3	
Mean (sd)	56.4 (18.2)	60.3 (18.3)	58.6 (18.4)	
Q1, Q3	46.2, 68.2	49.7, 73.1	48.2, 70.9	
Range	0.0 - 100.4	0.0 - 96.5	0.0 - 100.4	
N	330	413	743	
Age group (y)				0.014 ³
0-19	11 (3.3%)	11 (2.7%)	22 (3.0%)	
20-44	64 (19.4%)	71 (17.2%)	135 (18.2%)	
45-54	62 (18.8%)	60 (14.5%)	122 (16.4%)	
55-64	80 (24.2%)	83 (20.1%)	163 (21.9%)	
65-74	72 (21.8%)	102 (24.7%)	174 (23.4%)	
75-84	30 (9.1%)	62 (15.0%)	92 (12.4%)	
>=85	11 (3.3%)	24 (5.8%)	35 (4.7%)	
N	330	413	743	
Ethnicity				0.721 ¹
Hispanic/Latino	15 (30.6%)	15 (39.5%)	30 (34.5%)	
Not Hispanic/Latino	22 (44.9%)	14 (36.8%)	36 (41.4%)	
Not Specified	12 (24.5%)	9 (23.7%)	21 (24.1%)	
N	49	38	87	
Race				0.314 ¹
Asian	24 (7.3%)	19 (4.6%)	43 (5.8%)	
Black or African American	57 (17.3%)	66 (16.0%)	123 (16.6%)	
Caucasian	81 (24.5%)	115 (27.8%)	196 (26.4%)	
Declined	55 (16.7%)	47 (11.4%)	102 (13.7%)	
Other	62 (18.8%)	91 (22.0%)	153 (20.6%)	
Pacific Islander	3 (0.9%)	3 (0.7%)	6 (0.8%)	
Unavailable	48 (14.5%)	72 (17.4%)	120 (16.2%)	
N	330	413	743	
Highest level of care				0.241 ¹
Admitted	12 (27.9%)	11 (29.7%)	23 (28.8%)	
Discharged from ED	5 (11.6%)	1 (2.7%)	6 (7.5%)	

	Pos2neg (N=330)	Unchanged pos (N=413)	Total (N=743)	p value
ICU-level Care	22 (5.2%)	15 (40.5%)	37 (46.2%)	
Outpatient	4 (9.3%)	10 (27.0%)	14 (17.5%)	
N	43	37	80	
Encounter type at order				< 0.001 ¹
Emergency	19 (5.8%)	56 (13.6%)	75 (10.1%)	
Inpatient	216 (65.5%)	278 (67.3%)	494 (66.5%)	
Outpatient	95 (28.8%)	79 (19.1%)	174 (23.4%)	
N	330	413	743	
Location at order				0.018 ¹
Allen Hospital	9 (2.7%)	18 (4.4%)	27 (3.6%)	
Columbia	162 (49.1%)	165 (40.0%)	327 (44.0%)	
Columbia Outreach	0 (0.0%)	8 (1.9%)	8 (1.1%)	
Lower Manhattan	7 (2.1%)	11 (2.7%)	18 (2.4%)	
Queens	35 (10.6%)	73 (17.7%)	108 (14.5%)	
Weill Cornell	114 (34.5%)	136 (32.9%)	250 (33.6%)	
Westchester	3 (0.9%)	2 (0.5%)	5 (0.7%)	
N	330	413	743	
Number of admissions				0.629 ²
Median	1.0	1.0	1.0	
Mean (sd)	0.7 (0.5)	0.8 (0.7)	0.8 (0.6)	
Q1, Q3	0.0, 1.0	0.0, 1.0	0.0, 1.0	
Range	0.0 - 2.0	0.0 - 2.0	0.0 - 2.0	
N	49	38	87	
Admission duration (d)				0.314 ²
Median	22.9	6.6	12.3	
Mean (sd)	17.6 (16.4)	13.1 (13.0)	15.7 (15.1)	
Q1, Q3	0.4, 28.3	1.0, 27.7	0.7, 28.2	
Range	0.0 - 82.2	0.2 - 38.6	0.0 - 82.2	
N	49	38	87	
Admission 1 to test 1 (d)				0.014 ²
Median	28.1	20.6	25.7	
Mean (sd)	28.3 (10.4)	20.7 (12.2)	24.7 (11.9)	
Q1, Q3	23.1, 33.4	12.2, 31.5	16.3, 32.9	
Range	0.8 - 69.0	0.4 - 42.6	0.4 - 69.0	
N	43	38	81	
Admission 2 to test 1 (d)				0.182 ²
Median	8.6	0.2	0.3	
Mean (sd)	11.8 (12.3)	3.8 (8.1)	6.4 (10.2)	

	Pos2neg (N=330)	Unchanged pos (N=413)	Total (N=743)	p value
Q1, Q3	0.7, 21.3	0.2, 1.5	0.2, 8.3	
Range	0.2 - 32.6	0.1 - 28.3	0.1 - 32.6	
N	8	16	24	
Primary Outcome				0.241 ¹
Deceased/Discharged to Hospice	1 (2.0%)	3 (7.9%)	4 (4.6%)	
Discharged (not death)	24 (49.0%)	24 (63.2%)	48 (55.2%)	
Intubated (still admitted)	17 (34.7%)	10 (26.3%)	27 (31.0%)	
Still admitted (not intubated)	7 (14.3%)	1 (2.6%)	8 (9.2%)	
N	49	38	87	
Deceased				0.314 ¹
No	48 (98.0%)	35 (92.1%)	83 (95.4%)	
Yes	1 (2.0%)	3 (7.9%)	4 (4.6%)	
N	49	38	87	
Symptomatic				
No	1 (2.5%)	2 (8.7%)	3 (4.8%)	
Unknown	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Yes	39 (97.5%)	21 (91.3%)	60 (95.2%)	
N	40	23	63	
Symptoms start to death (d)				0.327 ²
Median	39.6	13.7	22.0	
Mean (sd)	39.6 (NA)	18.2 (10.6)	23.5 (13.8)	
Q1, Q3	39.6, 39.6	12.1, 22.0	12.9, 32.6	
Range	39.6 - 39.6	10.6 - 30.3	10.6 - 39.6	
N	1	3	4	
Any fever				0.744 ¹
No	11 (28.2%)	5 (23.8%)	16 (26.7%)	
Yes	28 (71.8%)	16 (76.2%)	44 (73.3%)	
N	39	21	60	
Intubated				0.327 ¹
No	26 (53.1%)	25 (65.8%)	51 (58.6%)	
Yes	23 (46.9%)	13 (34.2%)	36 (41.4%)	
N	49	38	87	
Extubated				0.128 ¹
No	44 (89.8%)	38 (100.0%)	82 (94.3%)	
Yes	5 (10.2%)	0 (0.0%)	5 (5.7%)	
N	49	38	87	

	Pos2neg (N=330)	Unchanged pos (N=413)	Total (N=743)	p value
Symptoms start to intubation (d)				0.721 ²
Median	10.0	9.0	9.0	
Mean (sd)	10.5 (5.6)	11.6 (8.1)	10.9 (6.4)	
Q1, Q3	8.0, 13.0	6.5, 19.0	7.0, 14.2	
Range	0.0 - 23.0	2.0 - 25.0	0.0 - 25.0	
N	21	11	32	
Intubation duration (d)				
Median	11.0	NA	11.0	
Mean (sd)	11.8 (5.1)	NA	11.8 (5.1)	
Q1, Q3	11.0, 11.0	NA	11.0, 11.0	
Range	6.0 - 20.0	NA	6.0 - 20.0	
N	5	0	5	
Decompensated				0.343 ¹
No	25 (51.0%)	24 (63.2%)	49 (56.3%)	
Yes	24 (49.0%)	14 (36.8%)	38 (43.7%)	
N	49	38	87	
Symptoms start to decompensation (d)				0.980 ²
Median	10.0	9.0	9.5	
Mean (sd)	11.8 (8.1)	11.7 (7.7)	11.8 (7.9)	
Q1, Q3	8.0, 13.8	6.8, 18.0	7.0, 14.8	
Range	0.0 - 39.0	2.0 - 25.0	0.0 - 39.0	
N	22	12	34	
Symptoms start to first test (d)				0.314 ²
Median	5.8	7.0	6.2	
Mean (sd)	6.7 (5.1)	24.0 (78.8)	12.9 (47.6)	
Q1, Q3	2.2, 9.1	2.5, 8.6	2.3, 9.0	
Range	-1.3 - 19.4	0.6 - 366.8	-1.3 - 366.8	
N	37	21	58	
Number of tests				< 0.001 ²
Median	3.0	2.0	2.0	
Mean (sd)	3.2 (2.4)	2.3 (0.6)	2.7 (1.7)	
Q1, Q3	2.0, 4.0	2.0, 2.0	2.0, 3.0	
Range	2.0 - 41.0	2.0 - 7.0	2.0 - 41.0	
N	330	413	743	
Number of positive results per patient				< 0.001 ²
Median	1.0	2.0	2.0	
Mean (sd)	1.4 (1.2)	2.0 (0.6)	1.8 (1.0)	
Q1, Q3	1.0, 2.0	2.0, 2.0	1.0, 2.0	

	Pos2neg (N=330)	Unchanged pos (N=413)	Total (N=743)	p value
Range	1.0 - 20.0	1.0 - 7.0	1.0 - 20.0	
N	330	413	743	

1. Pearson's Chi-squared test (adjusted for multiple comparisons)
2. Linear Model ANOVA (adjusted for multiple comparisons)
3. Trend test for ordinal variables (adjusted for multiple comparisons)

Supplementary Table 8: Characteristics of repeat-tested initially negative patients comparing those that converted from negative to positive (Neg2pos), with those that remained negative (Unchanged neg) or indeterminate (Unchanged ind) patients.

	Neg2pos (N=417)	Pos2neg (N=4)	Unchanged ind (N=43)	Unchanged neg (N=1705)	Total (N=2169)	p value
Gender at birth						0.062 ¹
Female	192 (46.0%)	1 (25.0%)	20 (46.5%)	900 (52.8%)	1113 (51.3%)	
Male	225 (54.0%)	3 (75.0%)	23 (53.5%)	805 (47.2%)	1056 (48.7%)	
N	417	4	43	1705	2169	
Age at order						< 0.001 ²
Median	63.6	68.1	63.4	57.1	58.9	
Mean (sd)	61.3 (18.8)	65.9 (6.7)	61.4 (14.4)	51.6 (26.2)	53.7 (25.1)	
Q1, Q3	49.1, 75.0	64.8, 69.2	52.1, 71.6	33.6, 72.0	36.3, 72.7	
Range	0.0 - 97.4	56.0 - 71.1	31.3 - 86.4	0.0 - 120.3	0.0 - 120.3	
N	417	4	43	1705	2169	
Age group (y)						< 0.001 ³
0-19	4 (1.0%)	0 (0.0%)	0 (0.0%)	238 (14.0%)	242 (11.2%)	
20-44	85 (20.4%)	0 (0.0%)	7 (16.3%)	401 (23.5%)	493 (22.7%)	
45-54	47 (11.3%)	0 (0.0%)	7 (16.3%)	172 (10.1%)	226 (10.4%)	
55-64	84 (20.1%)	1 (25.0%)	12 (27.9%)	248 (14.5%)	345 (15.9%)	
65-74	93 (22.3%)	3 (75.0%)	8 (18.6%)	301 (17.7%)	405 (18.7%)	
75-84	61 (14.6%)	0 (0.0%)	7 (16.3%)	221 (13.0%)	289 (13.3%)	
>=85	43 (10.3%)	0 (0.0%)	2 (4.7%)	124 (7.3%)	169 (7.8%)	
N	417	4	43	1705	2169	
Ethnicity						
Hispanic / Latino	23 (41.1%)	0	1 (100.0%)	25 (28.4%)	49 (33.8%)	
Not Hispanic/ Latino	22 (39.3%)	0	0 (0.0%)	44 (50.0%)	66 (45.5%)	
Not Specified	11 (19.6%)	0	0 (0.0%)	19 (21.6%)	30 (20.7%)	
N	56	0	1	88	145	
Race						0.085 ¹
Asian	30 (7.2%)	1 (25.0%)	1 (2.3%)	120 (7.0%)	152 (7.0%)	
Black or African American	88 (21.1%)	1 (25.0%)	9 (20.9%)	295 (17.3%)	393 (18.1%)	
Caucasian	94 (22.5%)	0 (0.0%)	10 (23.3%)	530 (31.1%)	634 (29.2%)	
Declined	49 (11.8%)	0 (0.0%)	7 (16.3%)	245 (14.4%)	301 (13.9%)	
Other	86 (20.6%)	1 (25.0%)	11 (25.6%)	279 (16.4%)	377 (17.4%)	
Pacific Islander	1 (0.2%)	0 (0.0%)	0 (0.0%)	4 (0.2%)	5 (0.2%)	
Unavailable	69 (16.5%)	1 (25.0%)	5 (11.6%)	232 (13.6%)	307 (14.2%)	
N	417	4	43	1705	2169	

	Neg2pos (N=417)	Pos2neg (N=4)	Unchanged ind (N=43)	Unchanged neg (N=1705)	Total (N=2169)	p value	
Highest level of care							
Admitted	30 (53.6%)	0	1 (100.0%)	43 (50.0%)	74 (51.7%)		
Discharged from ED	2 (3.6%)	0	0 (0.0%)	3 (3.5%)	5 (3.5%)		
ICU-level Care	10 (17.9%)	0	0 (0.0%)	23 (26.7%)	33 (23.1%)		
Outpatient	14 (25.0%)	0	0 (0.0%)	17 (19.8%)	31 (21.7%)		
N	56	0	1	86	143		
Encounter type at order							
Emergency	84 (20.1%)	0 (0.0%)	3 (7.0%)	161 (9.4%)	248 (11.4%)	< 0.001 ¹	
Inpatient	228 (54.7%)	4 (100.0%)	26 (60.5%)	1130 (66.3%)	1388 (64.0%)		
Outpatient	105 (25.2%)	0 (0.0%)	14 (32.6%)	414 (24.3%)	533 (24.6%)		
N	417	4	43	1705	2169		
Location at order							
Allen Hospital	38 (9.1%)	0 (0.0%)	4 (9.3%)	67 (3.9%)	109 (5.0%)	< 0.001 ¹	
Columbia	178 (42.7%)	1 (25.0%)	21 (48.8%)	731 (42.9%)	931 (42.9%)		
Columbia Outreach	16 (3.8%)	0 (0.0%)	1 (2.3%)	39 (2.3%)	56 (2.6%)		
Lower Manhattan	11 (2.6%)	1 (25.0%)	3 (7.0%)	86 (5.0%)	101 (4.7%)		
Queens	100 (24.0%)	0 (0.0%)	1 (2.3%)	223 (13.1%)	324 (14.9%)		
Weill Cornell	69 (16.5%)	2 (50.0%)	12 (27.9%)	524 (30.7%)	607 (28.0%)		
Westchester	5 (1.2%)	0 (0.0%)	1 (2.3%)	35 (2.1%)	41 (1.9%)		
N	417	4	43	1705	2169		
Number of admissions							
Median	1.0	NA	1.0	1.0	1.0		
Mean (sd)	1.0 (0.8)	NA	1.0 (NA)	0.9 (0.6)	1.0 (0.7)		
Q1, Q3	0.0, 2.0	NA	1.0, 1.0	0.8, 1.0	0.0, 1.0		
Range	0.0 - 2.0	NA	1.0 - 1.0	0.0 - 2.0	0.0 - 2.0		
N	56	0	1	88	145		
Admission duration (d)							
Median	5.6	NA	2.9	7.4	7.2		
Mean (sd)	8.5 (8.1)	NA	2.9 (NA)	13.2 (15.6)	11.3 (13.3)		
Q1, Q3	1.4, 11.9	NA	2.9, 2.9	1.5, 18.4	1.5, 15.4		
Range	0.2 - 33.0	NA	2.9 - 2.9	0.0 - 83.5	0.0 - 83.5		
N	56	0	1	88	145		
Admission 1 to test 1 (d)							
Median	8.5	NA	1.6	13.2	9.5		
Mean (sd)	12.1 (11.7)	NA	1.6 (NA)	17.5 (16.0)	15.3 (14.7)		
Q1, Q3	3.5, 20.3	NA	1.6, 1.6	3.3, 29.0	3.4, 25.7		

	Neg2pos (N=417)	Pos2neg (N=4)	Unchanged ind (N=43)	Unchanged neg (N=1705)	Total (N=2169)	p value
Range	0.5 - 42.9	NA	1.6 - 1.6	0.1 - 74.1	0.1 - 74.1	
N	56	0	1	87	144	
Admission 2 to test 1 (d)						
Median	0.2	NA	NA	1.2	0.3	
Mean (sd)	0.4 (0.9)	NA	NA	4.7 (8.0)	2.4 (5.9)	
Q1, Q3	0.1, 0.4	NA	NA	0.2, 4.1	0.1, 1.8	
Range	-3.8 - 2.0	NA	NA	0.0 - 33.0	-3.8 - 33.0	
N	33	0	0	29	62	
Primary Outcome						
Deceased/ Discharged to Hospice	7 (12.5%)	0	0 (0.0%)	9 (10.2%)	16 (11.0%)	
Discharged (not death)	43 (76.8%)	0	1 (100.0%)	68 (77.3%)	112 (77.2%)	
Intubated (still admitted)	3 (5.4%)	0	0 (0.0%)	1 (1.1%)	4 (2.8%)	
Still admitted (not intubated)	3 (5.4%)	0	0 (0.0%)	10 (11.4%)	13 (9.0%)	
N	56	0	1	88	145	
Deceased						
No	51 (91.1%)	0	1 (100.0%)	81 (92.0%)	133 (91.7%)	
Yes	5 (8.9%)	0	0 (0.0%)	7 (8.0%)	12 (8.3%)	
N	56	0	1	88	145	
Symptomatic						
No	1 (3.8%)	0	0 (0.0%)	0 (0.0%)	1 (3.4%)	
Unknown	1 (3.8%)	0	0 (0.0%)	1 (50.0%)	2 (6.9%)	
Yes	24 (92.3%)	0	1 (100.0%)	1 (50.0%)	26 (89.7%)	
N	26	0	1	2	29	
Symptoms start to death (d)						
Median	18.5	NA	NA	NA	18.5	
Mean (sd)	18.5 (10.7)	NA	NA	NA	18.5 (10.7)	
Q1, Q3	14.7, 22.3	NA	NA	NA	14.7, 22.3	
Range	10.9 - 26.1	NA	NA	NA	10.9 - 26.1	
N	2	0	0	0	2	
Any fever						
No	6 (24.0%)	0	0 (0.0%)	0 (0.0%)	6 (22.2%)	
Yes	19 (76.0%)	0	1 (100.0%)	1 (100.0%)	21 (77.8%)	
N	25	0	1	1	27	
Intubated						
No	49 (87.5%)	0	1 (100.0%)	71 (80.7%)	121 (83.4%)	

	Neg2pos (N=417)	Pos2neg (N=4)	Unchanged ind (N=43)	Unchanged neg (N=1705)	Total (N=2169)	p value
Yes	7 (12.5%)	0	0 (0.0%)	17 (19.3%)	24 (16.6%)	
N	56	0	1	88	145	
Extubated						
No	54 (96.4%)	0	1 (100.0%)	75 (85.2%)	130 (89.7%)	
Yes	2 (3.6%)	0	0 (0.0%)	13 (14.8%)	15 (10.3%)	
N	56	0	1	88	145	
Symptoms start to intubation (d)						
Median	11.0	NA	NA	7.0	10.5	
Mean (sd)	14.4 (11.5)	NA	NA	7.0 (NA)	13.2 (10.7)	
Q1, Q3	10.0, 21.0	NA	NA	7.0, 7.0	7.8, 18.5	
Range	0.0 - 30.0	NA	NA	7.0 - 7.0	0.0 - 30.0	
N	5	0	0	1	6	
Intubation duration (d)						
Median	3.5	NA	NA	3.0	3.0	
Mean (sd)	3.5 (3.5)	NA	NA	5.0 (5.6)	4.8 (5.2)	
Q1, Q3	2.2, 4.8	NA	NA	2.0, 5.0	2.0, 5.0	
Range	1.0 - 6.0	NA	NA	1.0 - 20.0	1.0 - 20.0	
N	2	0	0	12	14	
Decompensated						
No	46 (82.1%)	0	1 (100.0%)	68 (77.3%)	115 (79.3%)	
Yes	10 (17.9%)	0	0 (0.0%)	20 (22.7%)	30 (20.7%)	
N	56	0	1	88	145	
Symptoms start to decompensation (d)						
Median	16.0	NA	NA	7.0	11.0	
Mean (sd)	16.3 (11.3)	NA	NA	7.0 (NA)	15.0 (10.9)	
Q1, Q3	10.2, 24.7	NA	NA	7.0, 7.0	8.5, 23.5	
Range	0.0 - 30.0	NA	NA	7.0 - 7.0	0.0 - 30.0	
N	6	0	0	1	7	
Symptoms start to first test (d)						
Median	3.6	NA	9.1	4.4	4.4	
Mean (sd)	5.0 (5.2)	NA	9.1 (NA)	4.4 (NA)	5.1 (5.1)	
Q1, Q3	1.3, 7.8	NA	9.1, 9.1	4.4, 4.4	1.6, 7.9	
Range	-4.3 - 15.9	NA	9.1 - 9.1	4.4 - 4.4	-4.3 - 15.9	
N	25	0	1	1	27	
Number of tests						
Median	2.0	3.5	2.0	2.0	2.0	0.009 ²
Mean (sd)	2.4 (0.8)	3.5 (0.6)	2.3 (0.6)	2.5 (0.9)	2.5 (0.9)	
Q1, Q3	2.0, 3.0	3.0, 4.0	2.0, 2.0	2.0, 3.0	2.0, 3.0	

	Neg2pos (N=417)	Pos2neg (N=4)	Unchanged ind (N=43)	Unchanged neg (N=1705)	Total (N=2169)	p value
Range	2.0 - 9.0	3.0 - 4.0	2.0 - 5.0	2.0 - 8.0	2.0 - 9.0	
N	417	4	43	1705	2169	
Number of positive results per patient						< 0.001 ²
Median	1.0	1.0	1.0	0.0	0.0	
Mean (sd)	1.1 (0.3)	1.0 (0.0)	1.1 (0.6)	0.0 (0.0)	0.2 (0.5)	
Q1, Q3	1.0, 1.0	1.0, 1.0	1.0, 1.0	0.0, 0.0	0.0, 0.0	
Range	1.0 - 3.0	1.0 - 1.0	1.0 - 4.0	0.0 - 0.0	0.0 - 4.0	
N	417	4	43	1705	2169	

1. Pearson's Chi-squared test (adjusted for multiple comparisons)
2. Linear Model ANOVA (adjusted for multiple comparisons)
3. Trend test for ordinal variables (adjusted for multiple comparisons)